The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain

Neuroscience

Volumn 247, Issue , 2013, Pages 84-94

  Uhelski, M L ^a   Cain, D M ^a   Harding Rose, C ^a   Simone, D A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AM281; AM630; Electrophysiology; Mouse; Peripheral nerve; Tibial nerve

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DRUG MECHANISM; EVOKED RESPONSE; FIBROSARCOMA; HYPERALGESIA; MALE; MECHANICAL STIMULATION; MOUSE; NERVE FIBER C; NONHUMAN; PAIN RECEPTOR; PRIORITY JOURNAL; SENSITIZATION; STIMULUS RESPONSE; TUMOR GROWTH;

AM281; AM630; ANALYSIS OF VARIANCE; ANOVA; C-MECHANOHEAT NOCICEPTORS; C-MECHANONOCICEPTORS; CM; CMH; CONDUCTION VELOCITY; CV; DORSAL ROOT GANGLION; DRG; ELECTROPHYSIOLOGY; INTERQUARTILE RANGE; IQR; MOUSE; PBS; PERIPHERAL NERVE; PHOSPHATE-BUFFERED SALINE; PID; POST-IMPLANTATION DAY; TIBIAL NERVE; TRANSIENT RECEPTOR POTENTIAL; TRP; TRP ANKYRIN 1; TRP VANILLOID 1; TRPA1; TRPV1;

ANIMALS; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C3H; MORPHOLINES; NAPHTHALENES; NEOPLASMS; NERVE FIBERS, UNMYELINATED; NOCICEPTORS; PAIN;

EID: 84879267390     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.05.003     Document Type: Article

References (86)

1. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007, 10:870-879.
2. Ahluwalia J., Urban L., Bevan S., Capogna M., Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurons. Neuroscience 2002, 110:747-753.
3. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors in nociceptive primary sensory neurons. Neuroscience 2000, 100:685-688.
4. Akopian A.N., Ruparel N.B., Patwardhan A., Hargreaves K.M. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008, 28(5):1064-1075.
5. Basbaum A.I., Bautista D.M., Scherrer G., Julius D. Cellular and molecular mechanisms of pain. Cell 2009, 139(2):267-284.
6. Bridges D., Ahmad K., Rice A.S.C. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001, 133:586-594.
7. Burnstock G. A unifying purinergic hypothesis for the initiation of pain. Lancet 1996, 347:1604-1605.
8. Bridges D., Rice A.S., Egertova M., Elphick M.R., Winter J., Michael G.J. Localization of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridization and immunohistochemistry. Neuroscience 2003, 119(3):803-812.
9. Cain D.M., Wacnik P.W., Eikmeier L., Beitz A., Wilcox G.L., Simone D.A. Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2001, 2(1):15-23.
10. Calignano A., La Rana G., Giuffida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
11. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003, 111:43-50.
12. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96:253-260.
13. De Petrocellis L., Ligresti A., Moriello A.S., Allarà M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011, 163(7):1479-1494.
14. Desroches J., Guindon J., Lambert C., Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidononyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008, 155:913-924.
15. Elmes S.J.R., Winyard L.A., Medhurst S.J., Clayon N.M., Wilson A.W., Kendall D.A., Chapman V. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005, 118:327-335.
16. Falk S., Uldall M., Heegaard A.M. The role of purinergic receptors in cancer-induced bone pain. J Osteoporos 2012, published online October 3, 2012.
17. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995, 92(8):3376-3380.
18. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001, 92:91-100.
19. Fride R., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993, 231(2):313-314.
20. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Fur G.L.E., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte populations. Eur J Biochem 1995, 232(1):54-61.
21. Ghilardi J.R., Rohrich H., Lindsay T.H., Sevcik M.A., Schwei M.J., Kubota K., Halvorson K.G., Poblete J., Chaplan S.R., Dubin A.E., Carruthers N.I., Swanson D., Kuskowski M., Flores C.M., Julius D, Mantyh PW Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005, 25(12):3126-3131.
22. 3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Res 2005, 1044:197-205.
23. Griffin G., Tao Q., Abood M.E. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pharmacol Exp Ther 2000, 292(3):886-894.
24. Guerrero A.V., Quang P., Dekker N., Jordan R.C.K., Schmidt B.L. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett 2008, 433:77-81.
25. Guindon J., Desroches J., Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidononyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 2007, 150:693-701.
26. Hald A., Ding M., Egerod C., Hansen R.R., Konradsen D., Jorgensen S.G., Atalay B., Nasser A., Bjerrum O.J., Heegaard A.-M. Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 2008, 91:38-46.
27. Hamamoto D.T., Giridharagopalan S., Simone D.A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 2007, 558:73-87.
28. Hamamoto D.T., Khasabov S.G., Cain D.M., Simone D.A. Tumor-evoked sensitization of nociceptors: a role for endothelin. J Neurophysiol 2008, 100:2300-2311.
29. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997, 221:157-160.
30. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999, 90:923-931.
31. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (Eds.), SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD.based on November 2010 SEER data submission, posted to the SEER web site, 2011. http://seer.cancer.gov/csr/1975_2008/.
32. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., Malan T.P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003, 100:10529-10533.
33. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., Malan T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Br J Pharmacol 2005, 102:3093-3098.
34. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001, 93:303-315.
35. 2/3 receptors attenuates bone cancer pain behaviour in rats. Brain 2010, 133:2549-2564.
36. Kehl L.J., Hamamoto D.T., Wacnik P.W., Croft D.L., Norsted B.D., Wilcox G.L., Simone D.A. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003, 103:175-186.
37. Khasabova I.A., Chandiramani A., Harding-Rose C., Simone D.A., Seybold V.S. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 2011, 64:60-67.
38. Khasabova I.A., Harding-Rose C., Simone D.A., Seybold V.S. Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci 2004, 18:1744-1753.
39. Khasabova I.A., Khasabov S.G., Harding-Rose C., Coicou L.G., Seybold B.A., Lindberg A.E., Steevens C.D., Simone D.A., Seybold V.S. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 2008, 29:11141-11152.
40. 2+ influx in intermediate-size primary afferent neurons of adult rats. Neuroscience 2002, 115:613-625.
41. Khasabova I.A., Stucky C.L., Harding-Rose C., Eikmeier L., Beitz A.J., Coicou L.G., Hanson A.E., Simone D.A., Seybold V.S. Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci 2007, 19:10289-10298.
42. + currents in rat dorsal root ganglion neurons. Brain Res 2005, 1062:39-47.
43. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., Friedman H. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74:486-496.
44. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology 1999, 143:322-326.
45. Krishtal O., Lozovaya N., Fedorenko A., Savelyev I., Chizhmakov I. The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. Pflugers Arch 2006, 453(3):353-360.
46. Li J., Daughters R.S., Bullis C., Bengiamin R., Stucky M.W., Brennan J., Simone D.A. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999, 81:25-33.
47. Maehara Y., Kusumoto H., Anai H., Kusumoto T., Sugimachi K. Human tumor tissues have higher ATP contents than normal tissues. Clin Chim Acta 1987, 169:341-343.
48. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999, 82:199-205.
49. Menéndez L., Juárez L., Garcia E., García-Suárez O., Hidalgo A., Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett. 2006, 393(1):70-73.
50. Mercadante S., Portenoy R.K. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001, 21(2):144-150.
51. Mercadante S., Zagonel V., Breda E., Arcara C., Gebbia V., Porzio G., Aielli F., David F., Gammucci T., Narducci F., Lanzetta G., Restuccia R., Lembo A., Passeri V., Virzi V., Casuccio A. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage 2010, 40(2):183-190.
52. Meuser T., Pietruck C., Radbruch L., Stute P., Lehmann K.A., Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93:247-257.
53. 9-tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol 1980, 61:313-315.
54. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
55. Nackley A.G., Zvonok A.M., Makriyannis A., Hohmann A.G. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 2004, 92:3562-3574.
56. Noyes R., Brunk S.F., Avery D.H., Canter A. Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients. Compr Psychiatry 1976, 17(5):641-646.
57. Noyes, Brunk S.F., Avery J.A., Canter A.C. The analgesic properties of delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 1975, 18:84-89.
58. Noyes R., Brunk S.F., Baram D.A., Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975, 15:139-143.
59. Niiyama Y., Kawamata T., Yamamoto J., Omote K., Namiki A.I. Bone cancer increases trancient receptor potential vaniiloid subfamily 1 expression within distinct subpopulations of dorsal root ganglian neurons. Neurosci 2007, 148(2):560-572.
60. Nurmikko T.J., Serpell M.G., Hoggart B., Toomey P.J., Morlion B.J., Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007, 133:210-220.
61. Patwardhan A.M., Jeske N.A., Price T.J., Gamper N., Akopian A.N., Hargreaves K.M. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci 2006, 103(30):11393-11398.
62. Potenzieri C., Brink T.S., Pacharinsak C., Simone D.A. Cannabinoid modulation of cutaneous Aδ nociceptors during inflammation. J Neurophysiol 2008, 100:2794-2806.
63. Potenzieri C., Harding-Rose C., Simone D.A. The cannabinoid receptor agonist, WIN 55,212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008, 1215:69-75.
64. Price T.J., Helesic G., Parghi D., Hargreaves K.M., Flores C.M. The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 2003, 120:155-162.
65. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977, 21:26-33.
66. Rice A.S.C., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002, 66:243-256.
67. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998, 345:145-153.
68. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75:111-119.
69. Rukwied R., Watkinson A., McGlone F., Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102:283-288.
70. Rustøen T., Moum T., Padilla G., Paul S., Miaskowski C. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 2005, 30(3):234-242.
71. Saghafi N., Lam D.K., Schmidt B.L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett 2011, 488:247-251.
72. Salio C., Cottone E., Conrath M., Franzoni M.F. CB1 cannabinoid receptors in amphibian spinal cord: relationships with some nociception markers. J Chem Neuroanat 2002, 24:153-162.
73. Sántha P., Jenes A., Somogyi C., Nagy I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. Acta Physiol Hung 2010, 97(2):149-158.
74. Shinoda M., Ogino A., Ozaki N., Urano H., Hironaka K., Yasui M., Sugiura Y. Involvement of TRPV1 in nociceptive behaviour in a rat model of cancer pain. J Pain 2008, 9(8):687-699.
75. Shen J.J., Liu C.J., Li A., Hu X.W., Lu Y.L., Chen L., Zhou Y., Liu L.J. Cannabinoids inhibit ATP-activated currents in rat trigeminal ganglionic neurons. Sheng Li Xue Bao 2007, 59(6):745-752.
76. Stucky C.L., Dubin A.E., Jeske N.A., Malin S.A., McKemy D.D., Story G.M. Roles of transient receptor potential channels in pain. Brain Res Rev 2009, 60(1):2-23.
77. van den Beuken-van Everdingen M.H.J., de Rijke J.M., Kessels A.G., Schouten H.C., van Kleef M., Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40years. Ann Oncol 2007, 18(9):1437-1449.
78. Vasquez C., Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 1999, 1:9271-9280.
79. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., Wilcox G.L. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 2001, 21(23):9355-9366.
80. Walczak J.S., Price T.J., Cervero F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience 2009, 159(3):1154-1163.
81. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacol Ther 2002, 95:127-135.
82. Wu J.X., Xu M.Y., Miao X.R., Lu Z.J., Yuan X.M., Li X.Q., Yu W.F. Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. Eur J Pain 2012, 16(10):1378-1388.
83. Yesilyurt O., Dogrul A., Gul H., Seyrek M., Kusmez O., Ozkan Y., Yildiz O. Topical cannabinoid enhances topical morphine antinociception. Pain 2003, 105:303-308.
84. Yohn J.J., Morelli J.G., Walchak S.J., Rundell K.B., Norris D.A., Zamora M.R. Cultured human keratinocytes synthesize and secrete endothelin-1. J Invest Dermatol 1993, 100:23-26.
85. Zeppetella G., O'Doherty C.A., Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000, 20(2):87-92.
86. Zimmerman M. Ethical guidelines for investigation of experimental pain in conscious animals. Pain 1983, 16:109-110.